Associations among cardiovascular and cerebrovascular diseases: Analysis of the nationwide claims-based JROAD-DPC dataset

Michikazu Nakai1*, Yoshitaka Iwanaga1, Yoko Sumita1, Shinichi Wada1, Haruhiko Hiramatsu1, Koji Iihara1, Takahide Kohro2, Issei Komuro3, Tomohiro Kuroda4, Tetsuya Matoba5, Masaharu Nakayama6, Kunihiro Nishimura1, Teruo Noguchi1, Tadamasa Takemura7, Teiji Tominaga8, Kazunori Toyoda1, Kenichi Tsujita9, Satoshi Yasuda10, Yoshihiro Miyamoto1, Hisao Ogawa11

1 National Cerebral and Cardiovascular Center, Suita, Japan, 2 Department of Medical Informatics, Jichi Medical University Hospital, Shimotsuke, Japan, 3 Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 4 Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, Kyoto, Japan, 5 Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 6 Department of Medical Informatics, Tohoku University Graduate School of Medicine, Sendai, Japan, 7 Graduate School of Applied Informatics, University of Hyogo, Kobe, Japan, 8 Department of Neurosurgery, Tohoku University Hospital, Tohoku University Graduate School of Medicine, Sendai, Japan, 9 Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, 10 Department of Cardiovascular Medicine, Tohoku University Hospital, Tohoku University Graduate School of Medicine, Sendai, Japan, 11 President, Kumamoto University, Kumamoto, Japan

* nakai.michikazu@ncvc.go.jp

Abstract

Cardiovascular and cerebrovascular diseases are frequently interconnected due to underlying pathophysiology involving atherosclerosis and thromboembolism. The aim of this study was to investigate the impact of clinical interactions among cardiovascular and cerebrovascular diseases on patient outcomes using a large-scale nationwide claims-based dataset. Cardiovascular diseases were defined as myocardial infarction, heart failure, atrial fibrillation, and aortic dissection. Cerebrovascular diseases were defined as cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage. This retrospective study included 2,736,986 inpatient records (1,800,255 patients) at 911 hospitals from 2015 to 2016 from Japanese registry of all cardiac and vascular disease-diagnostic procedure combination dataset. Interactions among comorbidities and complications, rehospitalization, and clinical outcomes including in-hospital mortality were investigated. Among hospitalization records that involved cardiovascular disease, 5.9% (32,686 records) had cerebrovascular disease as a comorbidity and 2.1% (11,362 records) included an incident cerebrovascular complication after hospitalization. Cerebrovascular disease as a comorbidity or complication was associated with higher in-hospital mortality than no cerebrovascular disease (adjusted odds ratio (OR) [95% confidence interval]: 1.10 [1.06–1.14], 2.02 [1.91–2.13], respectively). Among 367,904 hospitalization records that involved cerebrovascular disease, 17.7% (63,647 records) had cardiovascular disease listed as comorbidity and 3.3% (11,834 records) as a complication. Only cardiovascular disease as a complication was associated with higher in-hospital mortality (adjusted OR [95% confidence interval]: 1.29 [1.22–1.37]). In
Introduction

According to the World Health Organization, cardiovascular and cerebrovascular diseases are the most frequent causes of death worldwide, accounting for 31% of all deaths in 2016 globally [1]. Both are frequently interconnected with common risk factors and underlying pathology such as atherosclerosis, a condition that damages medium and large arteries. In addition, cardiovascular risk factors are associated with the development of arrhythmias such as atrial fibrillation (AF), which predisposes a person to cerebrovascular events when blood clots in the atria and ventricles embolize to the brain. Thus, cardiovascular disease is a frequent cause of cerebrovascular compromise, and vice versa. For example, in older reports, approximately 2–6% of patients died from cardiac causes within 3 months of ischemic stroke [2, 3]. Ischemic stroke is a feared complication of acute myocardial infarction (MI), which is also a strong predictor of mortality [4]. Several cardiac disorders such as AF, valvular disease, and acute MI, are associated with an increased risk of ischemic stroke. Therefore, it is important to acknowledge not only the characteristics of each disease, but also the interrelationships among these diseases. Cardiovascular-cerebrovascular disorders require a multidisciplinary diagnostic and therapeutic approach [5].

Even though most previous studies have recognized the interaction among these diseases, they typically analyzed a dataset from a registry or cohort, which limits the sample size and the number of participating institutions [6, 7]. A comprehensive understanding of the associations among cardiovascular and cerebrovascular diseases and how they manifest as outcomes in clinical practice remains unclear in this era of big data. The aim of this study was to investigate the impact of clinical interactions among cardiovascular and cerebrovascular diseases on patient outcomes using a large-scale nationwide claims-based Japanese Registry Of All cardiac and cerebrovascular Disease-Diagnostic Procedure Combination (JROAD-DPC) dataset. First, clinical relationships and outcomes were investigated in terms of comorbidities and complications in hospitalized patients. Second, in-hospital mortality was assessed in the rehospitalization analysis of cardiovascular and cerebrovascular diseases.

Methods

Data source

The Diagnosis Procedure Combination (DPC), which is maintained by the Ministry of Health, Labour and Welfare of Japan, is a patient classification method for inpatients in the acute phase of illness. It has been developed as an assessment tool intended to make acute inpatient care transparent and to standardize, evaluate, and improve the quality of Japanese medical care. In the DPC dataset, all procedures and prescriptions during hospitalization are recorded according to the Japanese fee schedule for reimbursement [8, 9]. The Japanese Circulation Society has developed a nationwide claim database, JROAD-DPC, using data from the...
Identification of patients hospitalized with cardiovascular or cerebrovascular disease was conducted previously; details have been described elsewhere [8, 11]. The International Classification of Diseases (ICD)-10 diagnosis codes were I21, I22, I24 for MI, I50 for HF, I48 for AF, and I71.0 for AD. Cerebrovascular diseases were defined as cerebral infarction (CI), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). ICD-10 codes were I63 for CI, I61 for ICH, and I60 for SAH.

Identification of patients hospitalized with cardiovascular or cerebrovascular disease was based on the index ICD-10 code in any of the following four data fields: main diagnosis, admission-precipitating diagnosis, most resource-consuming diagnosis, and second most resource-consuming diagnosis. Comorbidity was defined as the presence of the index ICD-10 code in the diagnostic category of comorbidity. Complication was defined as the presence of the index ICD-10 code in the field for main diagnosis, admission-precipitating diagnosis, most resource-consuming diagnosis, second most resource-consuming diagnosis, or diagnostic category of complication.

Study population

Data in the JROAD-DPC dataset from April 1, 2015 to March 31, 2017 were analyzed in this study. Records for scheduled hospitalizations and multiple admission on the same date were excluded. In addition, records with a disease listed as both a comorbidity and a complication were excluded from the final analysis (Fig 1).

Fig 1. Study flow charts for comorbidities and complications of cardiovascular and cerebrovascular diseases in JROAD-DPC. AD, aortic dissection; AF, atrial fibrillation; CI, cerebral infarction; HF, heart failure; ICH, intracerebral hemorrhage; JROAD-DPC, Japanese Registry Of All cardiac and vascular Disease-Diagnostic Procedure Combination; MI, myocardial infarction; SAH, subarachnoid hemorrhage.

https://doi.org/10.1371/journal.pone.0264390.g001
Rehospitalization analysis

When a patient is first hospitalized due to cardiovascular disease and rehospitalized due to cerebrovascular disease, two scenarios can be considered:

i. The cardiovascular disease can be a comorbidity and hospitalization due to cerebrovascular disease appeared in the first record

ii. Hospitalization due to cardiovascular disease can occur without prior cardiovascular disease as a comorbidity in the first record and rehospitalization due to cerebrovascular disease appeared in the second record.

A similar pattern can be adapted for the first hospitalization due to cerebrovascular disease and rehospitalization due to cardiovascular disease (Fig 2). In the comparison of mortality, the first hospitalization was defined as the first hospitalization due to cardiovascular or cerebrovascular disease without any comorbidities of the other disease during the study period.

Ethics statement

The study was conducted according to the 1964 Declaration of Helsinki and its later amendments. It was approved by the National Cerebral and Cardiovascular Center ethics committee (authorization number, M29-024-2).

Statistical analysis

Data are expressed as medians (inter-quartile range) for continuous variables. Categorical data are expressed as numbers (%). Two-sample tests of proportions were conducted. There were missing data for age in 10,065 (0.37%) records and for in-hospital costs for 15,357 (0.56%) records. The median value for these variables was calculated with the complete dataset. Univariate and multivariable multilevel mixed effects logistic regression models with institution as a random intercept were performed to estimate odds ratios (ORs) and 95% confidence intervals for in-hospital mortality. In order to improve the efficiency of the analysis, basic demographic

**Fig 2.** Study flow charts showing analyzes of rehospitalization for cardiovascular and cerebrovascular diseases.

AD, aortic dissection; AF, atrial fibrillation; CI, cerebral infarction; HF, heart failure; ICH, intracerebral hemorrhage; JROAD-DPC, Japanese Registry Of All cardiac and vascular Disease-Diagnostic Procedure Combination; MI, myocardial infarction; SAH, subarachnoid hemorrhage.

https://doi.org/10.1371/journal.pone.0264390.g002
variables were included in Model I and comorbidities that are strongly related to cardiovascular and cerebrovascular diseases were further included in Model II. Multivariable analysis was conducted with two models. Model I adjusted for age and sex. Model II adjusted for age, sex, and comorbidities (hypertension, diabetes mellitus, hyperlipidemia, and chronic kidney disease). In addition, all hospital costs and charges were converted into US dollars according to the current exchange rate (1 US dollar = 106.00 yen). All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA) and STATA 16.1 (College station, TX, USA).

**Results**

**Cardiovascular and cerebrovascular diseases as comorbidities and complications**

Among 2,736,986 records of 1,800,255 patients at 911 hospitals, 541,481 records were extracted as hospitalization due to cardiovascular disease and 364,625 records were extracted as hospitalization due to cerebrovascular disease (Fig 1). Among all records involving cardiovascular hospitalization, cerebrovascular comorbidities were observed in 32,686 (6.0%) records and cerebrovascular complications were observed in 11,362 (2.1%) records. Among all records, involving cerebrovascular hospitalization, cardiovascular comorbidities were observed in 63,647 (17.8%) records and cardiovascular complications were observed in 11,834 (3.3%) records. Patients with cardiovascular disease and cerebrovascular comorbidities or complications were elderly and had worse in-hospital outcomes such as in-hospital mortality, score for activities of daily living (ADL) at discharge, and LOS, than patients with no cerebrovascular disease (Table 1A). These outcomes were worse in patients with cerebrovascular complications than those with cerebrovascular comorbidities and hospitalization costs were higher. Similarly, in patients hospitalized due to cerebrovascular disease, there were significant differences in these outcomes among patients with cardiovascular comorbidities or complications versus no cardiovascular disease (Table 1B). However, these differences were smaller than the differences among patients hospitalized due to cardiovascular disease.

Table 2 showed the results of univariate and multivariable multilevel logistic analyses for in-hospital mortality. Of all records, involving cardiovascular disease with the no cerebrovascular disease group as a reference, OR (95% confidence interval) for in-hospital mortality with a cerebrovascular comorbidity and complication was 1.33 (1.28–1.37) and 2.16 (2.05–2.27) in the univariate analysis, 1.15 (1.11–1.19) and 2.02 (1.92–2.13) in Model I, and 1.10 (1.06–1.14) and 2.02 (1.91–2.13) in Model II, respectively. Having a cerebrovascular comorbidity or complication was associated with higher in-hospital mortality in patients hospitalized due to cardiovascular disease. Furthermore, of all records involving cerebrovascular disease with the no cardiovascular disease group as the referent, the OR (95% confidence interval) for in-hospital mortality with a cardiovascular comorbidity and complication was 1.10 (1.06–1.13) and 1.38 (1.31–1.46) in the univariate analysis, 0.96 (0.93–0.99) and 1.26 (1.19–1.33) in Model I, and 0.87 (0.85–0.90) and 1.29 (1.22–1.37) in Model II, respectively. Only the presence of a cardiovascular complication was associated with higher in-hospital mortality in patients hospitalized due to cerebrovascular disease.

Regarding the detailed diagnoses in the comorbidity and complication analysis (S1 Table), CI was the most common comorbidity or complication among all cardiovascular diseases (1.18–3.54%). For AD, CI as a complication was not associated with the in-hospital mortality. On the other hand, there appeared to be differences in incidence and in-hospital mortality among various cerebrovascular diseases (S2 Table). For CI, AF as a comorbidity or complication had the highest incidence (19.20% and 3.20%, respectively). Furthermore, for ICH, HF had the highest incidence for a complication (1.04%). Moreover, AF as a comorbidity and AF
Table 1. Patient characteristics and outcomes.

(A) Cardiovascular disease

| No cerebrovascular disease | Cerebrovascular comorbidity | Cerebrovascular complication |
|----------------------------|-----------------------------|-----------------------------|
| Number                     | 496,281                     | 32,686                      | 11,362                      |
| Age group, years           |                             |                             |                             |
| <60                        | 76 (66–85)                  | 81 (73–87)                  | 79 (69–86)                  |
| 60–69                      | 70,399 (14.2%)              | 1,560 (4.8%)                | 1,080 (9.6%)                |
| 70–79                      | 128,182 (25.9%)             | 8,169 (25.0%)               | 2,981 (26.4%)               |
| 80–89                      | 146,913 (29.7%)             | 13,114 (40.2%)              | 3,879 (34.4%)               |
| ≥90                        | 54,125 (10.9%)              | 5,594 (17.1%)               | 1,484 (13.2%)               |
| Male sex                   | 296,707 (59.8%)             | 18,320 (56.0%)              | 6,233 (54.9%)               |

Comorbidity

- Hypertension 264,709 (53.3%) 17,265 (52.8%) 5,808 (51.1%)
- Diabetes mellitus 122,750 (24.7%) 8,088 (24.7%) 2,742 (24.1%)
- Hyperlipidemia 137,506 (27.7%) 6,619 (20.3%) 2,556 (22.5%)
- Chronic kidney disease 55,099 (11.1%) 3,944 (12.1%) 1,141 (10.0%)
- Carlson score 2 (1–3) 3 (2–4) 2 (1–3)

Clinical outcome

- In-hospital mortality 45,741 (9.2%) 4,280 (13.1%) 1,935 (17.0%)
- ADL score at discharge 100 (55–100) 65 (5–100) 55 (0–100)
- Length of hospital stay, days 13 (7–22) 17 (9–23) 24 (13–41)
- Total cost of hospitalization, U.S. dollars 10,351 (5,305–19,260) 8,986 (5,130–16,875) 14,644 (7,983–26,296)

(B) Cerebrovascular disease

| No cardiovascular disease | Cardiovascular comorbidity | Cardiovascular complication |
|---------------------------|-----------------------------|-----------------------------|
| Number                    | 281,999                     | 63,647                      | 11,834                      |
| Age group, years          |                             |                             |                             |
| <60                       | 73 (64–82)                  | 80 (72–86)                  | 78 (69–85)                  |
| 60–69                     | 51,770 (18.4%)              | 3,508 (5.5%)                | 1,166 (9.9%)                |
| 70–79                     | 61,410 (21.8%)              | 8,743 (13.8%)               | 1,916 (16.3%)               |
| 80–89                     | 77,847 (27.7%)              | 18,432 (29.0%)              | 3,356 (28.5%)               |
| ≥90                       | 72,601 (25.8%)              | 24,280 (38.2%)              | 4,019 (34.2%)               |
| Male sex                  | 159,859 (56.7%)             | 34,697 (54.5%)              | 6,529 (55.2%)               |

Comorbidity

- Hypertension 150,755 (53.5%) 33,420 (52.5%) 6,421 (54.3%)
- Diabetes mellitus 62,246 (22.1%) 12,845 (20.2%) 3,077 (26.0%)
- Hyperlipidemia 68,516 (24.3%) 11,739 (18.4%) 2,922 (24.7%)
- Chronic kidney disease 10,805 (3.8%) 3,217 (5.1%) 677 (5.7%)
- Carlson score 1 (1–2) 2 (1–3) 2 (1–3)

Clinical outcome

- In-hospital mortality 27,217 (9.7%) 6,691 (10.5%) 1,521 (12.9%)
- ADL score at discharge 70 (5–100) 50 (0–100) 50 (0–100)
- Length of hospital stay, days 18 (10–32) 21 (12–36) 24 (14–40)
- Total cost of hospitalization, U.S. dollars 9,037 (5,245–15,850) 10,465 (6,158–17,434) 12,421 (7,377–21,889)

Values are expressed as numbers (%) or medians (IQR).

ADL, activities of daily living; IQR, inter-quartile range.

https://doi.org/10.1371/journal.pone.0264390.t001
as a complication were associated with decreased in-hospital mortality. In addition, for SAH, HF had the highest incidence as both a comorbidity (2.70%) and a complication (1.45%). Moreover, AF as a comorbidity or complication and HF as a complication were associated with lower in-hospital mortality.

Cardiovascular and cerebrovascular diseases in the rehospitalization analysis

In the rehospitalization analysis, patients with a first hospitalization and rehospitalization were compared (Fig 2). In Table 3, clinical data and outcomes in patients at first hospitalization and rehospitalization due to cardiovascular or cerebrovascular disease are shown by detailed diagnosis. For cardiovascular disease, the higher age and a higher proportion of females were observed at rehospitalization compared with at first hospitalization. Mortality was the highest for AD. HF accounted for the majority of in-hospital mortality. For cerebrovascular disease, the higher age and a higher proportion of females were also observed at rehospitalization compared with at first hospitalization. Mortality was the highest for SAH. CI accounted for the majority of in-hospital mortality.

For all cardiovascular diseases, in-hospital mortality rate during rehospitalization was significantly higher than that during first hospitalization (Fig 3A). In the detailed diagnosis analysis, mortality rate was higher for rehospitalization. Similarly, for all cerebrovascular diseases, mortality rate during rehospitalization was significantly higher than mortality rate during first hospitalization, which was also true in the detailed diagnosis analysis (Fig 3B).

Discussion

We analyzed the frequency and clinical characteristics of cardiovascular and cerebrovascular diseases as comorbidities and complications in order to clarify associations between these two types of diseases. We also investigated mortality rate during rehospitalization for each diagnosis and compared it to mortality rate during the first hospitalization. To the best of our knowledge, our study was the first to comprehensively analyze linkages between cardiovascular and cerebrovascular diseases using a large-scale DPC dataset.

Relationship between cardiovascular and cerebrovascular diseases as comorbidities and complications

In the present study, the proportion of patients hospitalized due to cerebrovascular disease who had a cardiovascular disease as a comorbidity or complication was higher than the

---

Table 2. Univariate and multivariable multilevel logistic regression results for in-hospital mortality.

|                      | Univariate | Model I     | Model II    |
|----------------------|------------|-------------|-------------|
| Cardiovascular disease |            |             |             |
| No cerebrovascular disease | 1.00       | 1.00        | 1.00        |
| Cerebrovascular comorbidity | 1.33 (1.28, 1.37) | 1.15 (1.11, 1.19) | 1.10 (1.06, 1.14) |
| Cerebrovascular complication | 2.16 (2.05, 2.27) | 2.02 (1.92, 2.13) | 2.02 (1.91, 2.13) |
| Cerebrovascular disease |            |             |             |
| No cardiovascular disease | 1.00       | 1.00        | 1.00        |
| Cardiovascular comorbidity | 1.10 (1.06, 1.13) | 0.96 (0.93, 0.99) | 0.87 (0.85, 0.90) |
| Cardiovascular complication | 1.38 (1.31, 1.46) | 1.26 (1.19, 1.33) | 1.29 (1.22, 1.37) |

Values are expressed as odds ratios (95% confidence intervals).
Model I adjusted for age and sex.
Model II adjusted for age, sex, and comorbidities (hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease).

https://doi.org/10.1371/journal.pone.0264390.t002
|                | Cardiovascular disease |                   |                   |                   |                   |
|----------------|-----------------------|-------------------|-------------------|-------------------|-------------------|
| **First hospitalization** |                       |                   |                   |                   |                   |
| Number         | 319,799               | 98,462            | 274,119           | 84,056            | 31,013            |
| Age, year      | 76 (66–85)            | 71 (62–80)        | 81 (73–87)        | 70 (62–78)        | 72 (63–81)        |
| Male sex       | 191,226 (59.8%)       | 70,801 (71.9%)    | 145,310 (53.0%)   | 54,594 (65.0%)    | 17,888 (57.7%)    |
| Comorbidity    |                       |                   |                   |                   |                   |
| Hypertension   | 171,377 (53.6%)       | 58,916 (59.8%)    | 146,501 (53.4%)   | 40,171 (47.8%)    | 19,414 (62.6%)    |
| Diabetes mellitus | 85,454 (26.7%)       | 28,210 (28.7%)    | 77,580 (28.3%)    | 14,626 (17.4%)    | 3,036 (9.8%)      |
| Hyperlipidemia | 92,038 (28.8%)        | 54,792 (55.7%)    | 56,627 (20.7%)    | 19,387 (23.1%)    | 5,859 (18.9%)     |
| Chronic kidney disease | 40,692 (12.7%) | 6,225 (6.3%) | 44,308 (16.2%) | 3,937 (4.7%) | 1,811 (5.8%) |
| Mortality rate, % | 11.17                | 12.58             | 10.59             | 1.15              | 19.31             |
| **Rehospitalization** |                       |                   |                   |                   |                   |
| Number         | 32,860                | 4,789             | 21,690            | 5,475             | 2,352             |
| Age, year      | 81 (73–87)            | 77 (69–84)        | 84 (77–89)        | 76 (68–83)        | 76 (67–83)        |
| Male sex       | 18,458 (56.2%)        | 3,210 (67.0%)     | 11,373 (52.4%)    | 3,401 (62.1%)     | 1,247 (53.0%)     |
| Comorbidity    |                       |                   |                   |                   |                   |
| Hypertension   | 17,066 (51.9%)        | 2,594 (54.2%)     | 10,964 (50.6%)    | 2,902 (53.0%)     | 1,380 (58.7%)     |
| Diabetes mellitus | 8,014 (24.4%)       | 1,415 (29.6%)     | 5,688 (26.2%)     | 1,007 (18.4%)     | 256 (10.9%)       |
| Hyperlipidemia | 6,752 (20.6%)         | 1,771 (37.0%)     | 3,651 (16.8%)     | 1,256 (22.9%)     | 403 (17.1%)       |
| Chronic kidney disease | 3,908 (11.9%) | 418 (8.7%) | 3,175 (14.6%) | 272 (5.0%) | 166 (7.1%) |
| Mortality rate, % | 14.77                | 20.38             | 15.15             | 2.85              | 24.36             |

|                | Cerebrovascular disease |                   |                   |                   |                   |
|----------------|------------------------|-------------------|-------------------|-------------------|-------------------|
| **First hospitalization** |                       |                   |                   |                   |                   |
| Number         | 321,499                | 240,419           | 78,029            | 26,161            |
| Age, year      | 75 (65–83)             | 76 (67–84)        | 72 (62–82)        | 66 (53–77)        |
| Male sex       | 179,945 (56.0%)        | 140,401 (58.4%)   | 43,784 (56.1%)    | 8,670 (33.1%)     |
| Comorbidity    |                       |                   |                   |                   |                   |
| Hypertension   | 170,604 (53.1%)        | 122,485 (51.0%)   | 49,469 (63.4%)    | 12,896 (49.3%)    |
| Diabetes mellitus | 70,781 (22.0%)       | 61,332 (25.5%)    | 12,180 (15.6%)    | 2,228 (8.5%)      |
| Hyperlipidemia | 75,795 (23.6%)         | 68,291 (28.4%)    | 9,372 (12.0%)     | 3,222 (12.3%)     |
| Chronic kidney disease | 13,422 (4.2%) | 10,378 (4.3%) | 3,595 (4.6%) | 407 (1.6%) |
| Mortality rate, % | 9.79                  | 5.54              | 16.82             | 28.16             |
| **Rehospitalization** |                       |                   |                   |                   |                   |
| Number         | 69,576                 | 60,839            | 7,691             | 1,438             |
| Age, year      | 80 (72–86)             | 80 (73–87)        | 78 (69–84)        | 73 (62–83)        |
| Male sex       | 37,731 (54.2%)         | 32,901 (54.1%)    | 4,576 (59.5%)     | 477 (33.2%)       |
| Comorbidity    |                       |                   |                   |                   |                   |
| Hypertension   | 36,347 (52.2%)         | 30,720 (50.5%)    | 5,107 (66.4%)     | 752 (52.3%)       |
| Diabetes mellitus | 14,224 (20.4%)       | 12,656 (20.8%)    | 1,472 (19.1%)     | 178 (12.4%)       |
| Hyperlipidemia | 12,839 (18.5%)         | 11,713 (19.3%)    | 1,013 (13.2%)     | 176 (12.2%)       |
| Chronic kidney disease | 3,723 (5.4%) | 3,171 (5.2%) | 508 (6.6%) | 60 (4.2%) |
| Mortality rate, % | 11.42                 | 9.79              | 19.46             | 35.95             |

Values are expressed as numbers (%) or medians (interquartile range).
AD, aortic dissection; AF, atrial fibrillation; CI, cerebral infarction; HF, heart failure; ICH, intracerebral hemorrhage; MI, myocardial infarction; SAH, subarachnoid hemorrhage.

https://doi.org/10.1371/journal.pone.0264390.t003
proportion of patients hospitalized due to cardiovascular disease who had a cerebrovascular disease as a comorbidity or complication. This finding might suggest that cerebrovascular disease often develops as a result of cardiovascular disease and that the acute phase of cerebrovascular disease is more unstable and prone to the development of cardiovascular disease [12]. In both conditions, comorbidity or complication status was associated with older age, higher in-hospital mortality rate, longer LOS, decreased ability to perform ADLs at discharge, and higher total cost of hospitalization. However, in patients hospitalized due to cardiovascular disease, the differences were more pronounced. Of note, incident cerebrovascular disease (complication) at the time of cardiovascular hospitalization was associated with the poorest prognosis, suggesting that it is a situation that merits close attention. Multivariable analysis for in-hospital mortality also supported the findings.

The etiology of CI is classified as atherothrombotic, cardioembolic, or lacunar based on the mechanism. There is a strong link between CI and cardiovascular diseases based on atherosclerosis and thromboembolism [13]. Thus, CI was the most common comorbidity and complication among patients hospitalized for any cardiovascular disease. Among cardiovascular diseases, AD tended to be a comorbidity or complication of cerebrovascular disease most frequently, which might be associated with abrupt and substantial hemodynamic changes in AD. A relationship between MI and stroke has been frequently reported [14]. Previous studies have shown an association between cerebrovascular disease and MI. Of 9,180 patients admitted for ICH, 64.9% of discharged patients who had in-hospital MI as a complication died, compared with 35.8% in the entire cohort [15]. A meta-analysis that included 39 studies and 65,996 patients showed that patients admitted for cerebrovascular disease have a relatively high risk of mortality rate due to MI [16]. In the present analysis, MI was not a common complication, but MI as a complication in patients with any cerebrovascular disease was associated with higher in-hospital mortality (OR, 3.30–9.04) in the multivariable analysis. Cautious care for incident MI is required during the management of patients hospitalized due to cerebrovascular disease. Among patients hospitalized for CI, AF was the most frequent comorbidity and complication. A registry that compared patients with CI based on whether they had AF as a comorbidity showed that those with AF had a higher risk of mortality; their 1-year mortality rate was 30.5% [17, 18]. In the present study, CI with AF as a comorbidity or complication was associated with higher in-hospital mortality (OR, 1.63 and 1.23, respectively) in the multivariable analysis. Furthermore, a recent guideline showed that AF remains a common high-risk condition for the onset of a second stroke, which was consistent with our results [19].

Fig 3. Comparison of in-hospital mortality between first hospitalization and rehospitalization due to cardiovascular disease (A) or cerebrovascular disease (B).

https://doi.org/10.1371/journal.pone.0264390.g003
Comparison of first hospitalization and rehospitalization due to cardiovascular or cerebrovascular disease

Mortality during rehospitalization was significantly higher than mortality during first hospitalization for both cardiovascular and cerebrovascular disease, regardless of etiology. However, for cerebrovascular disease, there were small differences in mortality between the first hospitalization and rehospitalization, especially for ICH. Although the precise reasons for the differences are unknown, ICH might not be strongly associated with cardiovascular diseases in general, but ICH might be associated with some specific cardiovascular diseases. Regarding incidence and the number of patients, prevention of incident HF is important in patients with cerebrovascular disease. It is important to prevent incident CI in patients with cardiovascular disease. In the present analysis, in-hospital mortality rate from MI and AF was substantially higher for rehospitalization than for first hospitalization. In contrast, in-hospital mortality for CI was substantially higher for rehospitalization than for the first hospitalization. Based on these differences in mortality rate, prevention of incident MI and AF is important in patients with cerebrovascular disease. Similarly, it is important to prevent incident CI in patients with cardiovascular disease.

Clinical implications

The current guidelines regarding secondary prevention of cardiovascular or cerebrovascular disease recommend strict control and intensive management of cardiovascular risk factors in “very high-risk” patients [20, 21]. All patients with atherosclerotic vascular disease are classified into a very high-risk group; however, the interplay between cardiovascular and cerebrovascular diseases is not considered. The present results suggest that more intensive prevention of progression and management of both cardiovascular and cerebrovascular disease are crucial. In addition, the present findings might be used by other researchers to design clinical trials, epidemiologic studies, and quality outcomes research studies regarding the associations between cardiovascular and cerebrovascular diseases. Such studies might identify more practical and effective prevention and therapeutic strategies to manage cardiovascular and cerebrovascular diseases.

Study limitations

This study had several limitations. First, since the present analysis was based on the DPC dataset, there are no data about laboratory results and imaging examinations, detailed etiology, and cause of death. Thus, more details about factors associated with mortality or rehospitalization could not be determined. Second, each institution was required to provide their DPC information annually and JROAD-DPC did not necessarily include consecutive DPC datasets. Therefore, these results might underestimate the probability of rehospitalization across the 2 years. Third, since the DPC dataset was a limited annual dataset in 2016 and 2017, the first hospitalization in this study does not necessarily mean the patient’s first-ever episode of disease during their lifetime. Instead, it reflects first-ever episode of disease during the year of interest. Finally, even though mortality and incidence of cerebrovascular disease in Japan are similar to those in Western countries, the mortality and incidence rates of cardiovascular disease in Japan are still lower than those in Western countries [22]. Thus, the present findings might be underestimated compared with those in Western countries. Further international or comparative studies are necessary.
Conclusions

Substantial associations were observed between cardiovascular and cerebrovascular disease in a Japanese nationwide claims-based dataset. Of note, patients hospitalized with cerebrovascular disease frequently had cardiovascular disease as a comorbidity or complication. These associations had a significant impact on clinical outcomes such as in-hospital mortality, LOS, and total medical costs during rehospitalization. In patients with cardiovascular or cerebrovascular disease, more intensive prevention and management of the other disease are crucial. Therefore, the significant association between cardiovascular and cerebrovascular disease might be an important theme for future research.

Supporting information

S1 Table. Univariate and multivariable analysis of comorbidities and complications for in-hospital mortality in patients with cardiovascular disease. Values are expressed as odds ratios (95% confidence interval). AD, aortic dissection; AF, atrial fibrillation; CI, cerebral infarction; HF, heart failure; ICH, intracerebral hemorrhage; MI, myocardial infarction; SAH, subarachnoid hemorrhage. Model I adjusted for age and sex. Model II adjusted for age, sex, and comorbidities (hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease). (DOCX)

S2 Table. Univariate and multivariable analysis of comorbidities and complications for in-hospital mortality in patients with cerebrovascular disease. Values are expressed as odds ratios (95% confidence interval). AD, aortic dissection; AF, atrial fibrillation; CI, cerebral infarction; HF, heart failure; ICH, intracerebral hemorrhage; MI, myocardial infarction; SAH, subarachnoid hemorrhage. Model I adjusted for age and sex. Model II adjusted for age, sex, and comorbidities (hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease). (DOCX)

Author Contributions

Conceptualization: Yoshitaka Iwanaga, Shinichi Wada, Haruhiko Hiramatsu, Koji Iihara, Takahide Kohro, Issei Komuro, Tomohiro Kuroda, Tetsuya Matoba, Masaharu Nakayama, Kunihiro Nishimura, Teruo Noguchi, Tadamasa Takemura, Teiji Tominaga, Kazunori Toyoda, Kenichi Tsujita, Satoshi Yasuda, Yoshihiro Miyamoto, Hisao Ogawa.

Data curation: Yoko Sumita, Shinichi Wada, Haruhiko Hiramatsu, Issei Komuro, Tomohiro Kuroda, Tetsuya Matoba, Masaharu Nakayama, Kunihiro Nishimura, Teruo Noguchi, Tadamasa Takemura, Teiji Tominaga, Kazunori Toyoda, Kenichi Tsujita, Satoshi Yasuda, Yoshihiro Miyamoto, Hisao Ogawa.

Formal analysis: Michikazu Nakai.

Methodology: Yoko Sumita.

Supervision: Yoshitaka Iwanaga, Koji Iihara, Issei Komuro, Tomohiro Kuroda, Masaharu Nakayama, Teruo Noguchi, Teiji Tominaga, Kazunori Toyoda, Kenichi Tsujita, Satoshi Yasuda, Yoshihiro Miyamoto, Hisao Ogawa.

Visualization: Shinichi Wada, Takahide Kohro.

Writing – original draft: Michikazu Nakai.

Writing – review & editing: Yoshitaka Iwanaga, Hisao Ogawa.


References

1. World Health Organization (2017). (http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). Accessed on 18 March, 2021.

2. Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective review. Stroke. 1984; 15:492–6. https://doi.org/10.1161/01.STR.0000090125.28466.E2 PMID: 6729678

3. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerquiera MD, Fayad P et al. American Heart Association/American Stroke Association. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke. 2003; 34:2310–22. https://doi.org/10.1161/01.STR.0000090125.28466.E2 PMID: 12958318

4. Kajermo U, Ulvenstam A, Modica A, Jernberg T, Mooe T. Incidence, trends, and predictors of ischemic stroke 30 days after an acute myocardial infarction. Stroke. 2014; 45:1324–30. https://doi.org/10.1161/STROKEAHA.114.005978 PMID: 24692479

5. Finsterer J, Stöllberger C. Neurological complications of cardiac disease (heart brain disorders). Minerva Med. 2016; 107:14–25.

6. Dhamoon MS, Tai W, Boden-Albala B, Rundek T, Paik MC, Sacco RL et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke. 2007; 38:1752–8. https://doi.org/10.1161/01.STR.0000280534.98416.A0 PMID: 17431206

7. Vernino S, Brown RD Jr, Seijvar JJ, Sicks JD, Petty GW, O’Fallon WM. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke. 2003; 34:1828–32. https://doi.org/10.1161/01.STR.0000090125.28466.E2 PMID: 12958318

8. Hayashida K, Murakami G, Matsuda S, Fushimi K. History and Profile of Diagnosis Procedure Combination (DPC): Development of a Real Data Collection System for Acute Inpatient Care in Japan. J Epidemiol. 2021; 31:1–11. https://doi.org/10.2188/jea.JE20200288 PMID: 33012777

9. Nakai M, Iwanaga Y, Sumita Y, Kanaoka K, Kawakami R, Ishii M et al. Validation of Acute Myocardial Infarction and Heart Failure Diagnoses in Hospitalized Patients with the Nationwide Claim-based JROAD-DPC database. Circ Rep. 2021; 3:131–136. https://doi.org/10.1253/circrep.CR-21-0004 PMID: 33738345

10. The Ministry of Health, Labour and Welfare in Japan (2017). Available from: https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000165672.pdf, Accessed on 17 July, 2021.

11. Yasuda S, Miyamoto Y, Ogawa H. Current Status of Cardiovascular Medicine in the Aging Society of Japan. Circulation. 2018; 138:965–967. https://doi.org/10.1161/CIRCULATIONAHA.118.035858 PMID: 30354536

12. Chen Z, Venkat P, Seyfried D, Chopp M, Yan T, Chen J. Brain-Heart Interaction: Cardiac Complications After Stroke. Circ Res. 2017; 121:451–468. https://doi.org/10.1161/CIRCRESAHA.117.311170 PMID: 28775014

13. Kim JS, Caplan LR. Clinical Stroke Syndromes. Front Neurol Neurosci. 2016; 40:72–92. https://doi.org/10.1159/000448303 PMID: 27960164

14. Conforto AB, Leite Cda C, Nomura CH, Bors-Seng-Shu E, Santos RD. Is there a consistent association between coronary heart disease and ischemic stroke caused by intracranial atherosclerosis? Arq Neuropsiquiatr. 2013; 71:320–6. https://doi.org/10.1590/0004-282x20130026 PMID: 23989410

15. Liao J, O’Donnell MJ, Silver FL, Thiruchelvam D, Saposnik G, Fang J, et al. In-hospital myocardial infarction following acute ischaemic stroke: an observational study. Eur J Neurol. 2009; 16:1035–40. https://doi.org/10.1111/j.1468-1331.2009.02847.x PMID: 19614964

16. Touzé É, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke. 2005; 36:2748–55. https://doi.org/10.1161/01.STR.0000190118.02273.35 PMID: 16254218

17. Kaarsalo MM, Immonen-Råhå P, Marttila RJ, Salomaa V, Kaarsalo E, Salmi K et al. Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke. 1997; 28:310–5. https://doi.org/10.1161/01.STR.0000080534.98416.A0 PMID: 9040681

18. Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The Epidemiology of Atrial Fibrillation and Stroke. Cardiol Clin. 2016; 34:255–68. https://doi.org/10.1016/j.ccl.2015.12.002 PMID: 27150174

19. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J, Lombardi-Hill D et al. 2021 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52:e364–e467. https://doi.org/10.1161/STR.0000000000000375 PMID: 34024117

20. Hasenfuß G. Secondary prevention of cardiovascular diseases: current state of the art. Kardiol Pol. 2018; 76:1671–1679. https://doi.org/10.5603/KP.a2018.0196 PMID: 30338502
21. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42:3227–3337. https://doi.org/10.1093/eurheartj/ehab484 PMID: 34458905

22. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008; 118:2702–9. https://doi.org/10.1161/CIRCULATIONAHA.108.790048 PMID: 19106393